The primary objective of the study is to assess the relationship (both crude and adjusted) between voriconazole utilization and the development of non-melanoma skin cancer among adult patients who received a lung or heart/lung transplant and were continuously enrolled in a large U.S. commercial health plan.
N/A. All patients aged 18 or older who received a lung or heart/lung transplant from January 1, 2002 through December 31, 2009 in the MarketScan database were sampled.
Study Type
OBSERVATIONAL
Enrollment
467
Voriconazole utilization was identified as any vs. none for the period 180 days before and 180 days after the date of transplant.
Voriconazole utilization was identified as any vs. none for the period 180 days before and 180 days after the date of transplant.
Number of Participants Who Developed Non-Melanoma Skin Cancer (NMSC)
Time frame: Baseline until non-melanoma skin cancer diagnosis, loss-to-follow-up due to death or termination of the health plan or end of the study, assessed up to Year 8
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.